Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in hepatocellular carcinoma after liver transplant
NCT04319484Phase 3Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- May 2020
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Planned start May 2020; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04319484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04319484.